Amicus Therapeutics Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
189.13 M |
Public Float |
187.04 M |
Amicus Therapeutics Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$2.14 |
Market Cap |
$3.02 B |
Shares Outstanding |
254.33 M |
Public Float |
217.92 M |
Address |
1 Cedar Brook Drive Cranbury New Jersey 08512 United States |
Employees | - |
Website | http://www.amicusrx.com |
Updated | 07/08/2019 |
Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |